BCLI Plans Coming Together for Phase 3b Trial of NurOwn in ALS

BCLI Stock  USD 2.16  0.03  1.41%   
Under 54% of Brainstorm Cell's traders are presently thinking to get in. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that some traders are interested. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
  
By David Bautz, PhD NASDAQBCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on Planned Phase 3b Trial of NurOwn in ALS On December 30, 2024, BrainStorm Cell Therapeutics, Inc. conducted an investor update call to provide a corporate update. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic lateral sclerosis .

Read at finance.yahoo.com
Yahoo News
  

Brainstorm Cell Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Brainstorm Cell Fundamental Analysis

We analyze Brainstorm Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Target Price

Target Price Comparative Analysis

Brainstorm Cell is currently under evaluation in target price category among its peers.

Brainstorm Cell Ther Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Brainstorm Cell stock to make a market-neutral strategy. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics with similar companies.

Peers

Brainstorm Cell Related Equities

CUECue Biopharma   14.88   
0%
100.0%
CKPTCheckpoint Therapeutics   6.50   
0%
43.0%
MREOMereo BioPharma   6.16   
0%
41.0%
XFORX4 Pharmaceuticals   6.12   
0%
41.0%
HOWLWerewolf Therapeutics   5.88   
0%
39.0%
TRVITrevi Therapeutics   5.56   
0%
37.0%
CELCCelcuity LLC   3.46   
0%
23.0%
PASGPassage Bio   3.33   
0%
22.0%
GRIGRI Bio   2.99   
0%
20.0%
ALDXAldeyra   2.86   
0%
19.0%
PLXProtalix Biotherapeutics   1.72   
0%
11.0%
INZYInozyme Pharma   1.54   
0%
10.0%
DAWNDay One   1.05   
0%
7.0%
CCCCC4 Therapeutics   0.81   
0%
5.0%
EWTXEdgewise Therapeutics   0.52   
3.0%
0%
TERNTerns Pharmaceuticals   0.64   
4.0%
0%
ANTXAN2 Therapeutics   0.79   
5.0%
0%
BCABBioatla   2.00   
13.0%
0%
CRVSCorvus Pharmaceuticals   2.57   
17.0%
0%
HCWBHCW Biologics   2.86   
19.0%
0%
CNTBConnect Biopharma   2.86   
19.0%
0%
GBIOGeneration Bio   3.03   
20.0%
0%

Complementary Tools for Brainstorm Stock analysis

When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Global Correlations
Find global opportunities by holding instruments from different markets